Pharmacologic Efficacy in Still's Disease
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s…
View Resource
Weak Data (1.24.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com. He features Dr.…
View Resource
Risks associated with mortality in VEXAS
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it…
View Resource
The Still’s Continua
The concept of a “Still’s disease continuum” that encompasses both sJIA and AOSD is…
View Resource
Do biologics help taper steroids in Adult Still’s Disease?
Adult Still’s Disease is labeled as a rare disease as the prevalence of the…
View Resource
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved…
View Resource
Cutoffs for Systemic Juvenile Arthritis Disease Activity Score
An international cohort of children with systemic Juvenile idiopathic arthritis (Still’s disease) validated the…
View Resource
The Cartel is Coming for Rheumatology
“What Do Blockbuster Drugs & The Black Market All Have in Common?” asked Dr.…
View Resource
Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles
Pulmonary complications in the setting of Still’s disease (both juvenile and adult) has seldom…
View Resource
Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients
JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated…
View Resource